Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATRC
HOLDAtriCure, Inc. · Healthcare · United States · $1.8B · Avg Vol: $38M/d
COMPANY DESCRIPTION
AtriCure, Inc. is a medical device company dedicated to developing, manufacturing, and selling products for the treatment of atrial fibrillation (Afib) and other cardiac arrhythmias. The company is a recognized market leader in surgical Afib solutions, offering a comprehensive portfolio of ablation systems and cryoablation products. AtriCure's competitive advantage stems from its strong intellectual property, extensive clinical evidence, and established surgeon relationships in this specialized field.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 330.4M | 399.2M | 465.3M | 534.5M | 17.4% | 552.2M | 606.2M | 679.3M | 12.7% |
| EPS | -1.02 | -0.66 | -0.95 | -0.24 | — | -0.10 | 0.26 | 0.45 | — |
| Shares | 46.6M | 47.5M | 48.9M | 49.8M | +6.9% | 50.6M | — | — | — |
| Debt | 74.5M | 74.5M | 73.7M | 73.4M | -0.5% | 74.9M | — | — | — |
| Equity | 456.8M | 466.2M | 461.0M | 491.9M | 2.5% | — | — | — | — |
| Op CF | -22.1M | 4.5M | 12.2M | 57.3M | 257.6% | 64.4M | — | — | — |
| Inv CF | 44.0M | 21.8M | 30.2M | -14.6M | — | — | — | — | — |
| Fin CF | -7.1M | -32.0K | -3.6M | 1.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATRC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATRC | AtriCure, Inc.(you) | $1.8B | 55 | HOLD |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
| STAA | STAAR Surgical Company | $1.2B | 55 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
| WRBY | Warby Parker Inc. | $3.0B | 42 | HOLD |
| LMAT | LeMaitre Vascular, Inc. | $2.2B | 76 | BUY |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| XRAY | DENTSPLY SIRONA Inc. | $2.6B | 74 | BUY |
| PLSE | Pulse Biosciences, Inc. | $2.1B | 24 | SELL |
| TFX | Teleflex Incorporated | $5.8B | 69 | BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%